Contrive Datum Insights has published "Famotidine Market Size, Share & Industry Analysis, By Formulation (Tablets, Injectables, Oral Suspension, Chewable Tablets), Type (Generic, Branded), Application (GERD (Gastroesophageal Reflux Disease), Heartburn and Acid Indigestion (OTC), Peptic Ulcer Disease, Zollinger-Ellison Syndrome and Other Hypersecretory Conditions), Distribution channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), Age group (Adult, Geriatric, Pediatric), and Regional Forecast, 2026-2034". The study sizes the global famotidine market at USD 1.95 billion in 2025 and projects growth from USD 2.03 billion in 2026 to USD 2.85 billion by 2034, a compound annual growth rate of 4.33% across the forecast period.
Famotidine is a histamine H2-receptor antagonist used to reduce gastric acid secretion in the treatment of gastroesophageal reflux disease, peptic ulcer disease and other acid-related conditions, and is available in prescription and over-the-counter forms including tablets, oral suspension, chewable tablets and injectable formulations. Buyers span hospital and retail pharmacies, physicians treating chronic acid-reflux and ulcer conditions, and individual consumers self-treating heartburn and acid indigestion through over-the-counter purchase. Both branded and generic versions are manufactured and distributed, with generic producers supplying the majority of volume sold through retail and institutional channels.
Rising global prevalence of GERD and other acid-related disorders
Rising global prevalence of GERD and other acid-related disorders is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 4.33% a year, the formulation lines exposed to it move fastest: Chewable Tablets compounds at 6.26%, taking its share of revenue from 8.21% to 9.12% and its value from USD 0.16 billion to USD 0.26 billion.
The study also runs a bull case: bull case assumes faster OTC-to-prescription substitution reversal and accelerated adoption of famotidine as a lower-cost alternative to PPIs across price-sensitive healthcare systems, alongside earlier-than-expected capacity expansion among generic manufacturers. That path ends 2034 at USD 3.14 billion, above the USD 2.85 billion base case.
Against that, bear case assumes intensified competition from proton pump inhibitors and other H2-blocker alternatives, tighter reimbursement policies in key markets, and slower-than-expected OTC channel expansion in emerging regions. On that reading 2034 revenue stops at USD 2.57 billion. The weight of the problem sits in Tablets: 62.05% of 2025 revenue growing at 3.53%, well under the market's 4.33%.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Generic | 77.95% · USD 1.52 billion | — |
| Application | GERD (Gastroesophageal Reflux Disease) | 45.13% · USD 0.88 billion | Heartburn and Acid Indigestion (OTC) 5.99% |
| Distribution channel | Retail Pharmacies | 54.87% · USD 1.07 billion | Online Pharmacies 11.24% |
| Age group | Adult | 57.95% · USD 1.13 billion | Pediatric 6.13% |
- Based on regional analysis, North America led the global famotidine market in 2025 with 33.85% of global revenue at USD 0.66 billion, reaching USD 0.86 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 28.21% in 2025 to 32.98% in 2034, with revenue growing from USD 0.55 billion to USD 0.94 billion.
- Middle East and Africa stays the smallest contributor across the period: 5.64% of revenue in 2025 and 5.61% in 2034.
- By formulation, the largest line in 2025 was Tablets, at 62.05% of revenue and USD 1.21 billion.
- Chewable Tablets is projected to grow at 6.26% over the forecast period, the fastest of any formulation line.
- The United States is the largest single country market at USD 0.58 billion in 2025, 29.74% of global revenue.
The report segments the market across five axes; by formulation, and by type, application, distribution channel and age group; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 2.57 billion and USD 3.14 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.